Association of easy albumin-bilirubin score with increased mortality in adult trauma patients

Abstract

Introduction:

The easy albumin-bilirubin (EZ-ALBI) score is calculated using the equation: total bilirubin (mg/dl) − 9 × albumin (g/dl), and is used to evaluate liver functional reserve. This study was designed to investigate whether the EZ-ALBI score serves as an independent risk factor for mortality and is useful for stratifying the mortality risk in adult trauma patients.

Methods:

We retrospectively reviewed data from the registered trauma database of the hospital and included 3,637 adult trauma patients (1,241 deaths and 2,396 survivors) due to all trauma caused between January 1, 2009, and December 31, 2021. The patients were allocated to the two study groups based on the best EZ-ALBI cutoff point (EZ-ALBI = −28.5), which was determined based on the area under the receiver operating characteristic curve.

Results:

Results revealed that the non-survivors had a significantly higher EZ-ALBI score than the survivors (−26.4 ± 6.5 vs. −31.5 ± 6.2, p < 0.001). Multivariate logistic regression analysis revealed that EZ-ALBI ≥ −28.5was an independent risk factor for mortality (odds ratio, 2.31; 95% confidence interval, 1.63–3.28; p < 0.001). Patients with an EZ-ALBI score ≥ −28.5 presented with 2.47-fold higher adjusted mortality rates than patients with an EZ-ALBI score < −28.5. A propensity score-matched pair cohort of 1,236 patients was developed to reduce baseline disparities in trauma mechanisms. The analysis showed that patients with an EZ-ALBI score ≥ −28.5 had a 4.12 times higher mortality rate compared to patients with an EZ-ALBI score < −28.5.

Conclusion:

The EZ-ALBI score was a significant independent risk factor for mortality and can serve as a valuable tool for stratifying mortality risk in adult trauma patients by all trauma causes.

Introduction

Because liver function is perceived as a competing issue related to patient mortality, the assessment of the liver function reserve is particularly important in the clinical setting (1). In addition to the traditional evaluation tools of the model for end-stage liver disease (MELD) score (2) or the Child-Turcotte-Pugh (CTP) classification (3), an alternative measure of liver function based solely on albumin and bilirubin, the albumin-bilirubin (ALBI) score, was proposed in international collaboration as a simple and objective method for the assessment of liver function in patients with hepatocellular carcinoma (4). Since its introduction, the ALBI score has been validated by several research groups to predict the outcome of patients with resectable or locally advanced hepatoma (5–9) as well as in those with advanced hepatoma receiving local or systemic therapy (6, 8–12). Additionally, it serves as an important biomarker for liver disease progression to reflect the possibility of hepatic failure and liver-related mortality (13–19). ALBI grade is also useful as a prognostic factor in patients with cholangiocarcinoma (20), intrahepatic cholangiocarcinoma (21), colorectal cancer with liver metastases (22), pancreatic cancer with liver metastases (23), and primary biliary cholangitis (24). Furthermore, a strong association between ALBI and mortality has been identified in many non-hepatological conditions, such as gastric cancer (25), lung cancer (16, 26, 27),esophageal cancer (28), glioma (29), medulloblastoma (30), heart failure (31, 32), acute pancreatitis (33), and aortic dissection (34).

The ALBI score is calculated using the following formula: [(log10 bilirubin (μmol/L) × 0.66) + [albumin (g/L) × −0.0852]. The complexity of the calculation of the ALBI score limits its applicability. Therefore, an easy-ALBI (EZ-ALBI) score was recently developed to replace the ALBI score based on the regression coefficients of serum albumin and bilirubin levels using a multivariate Cox proportional hazards model, and calculated by the equation: total bilirubin (mg/dl) − 9 × albumin (g/dl) (35). The EZ-ALBI score showed a high linear correlation (correlation coefficient, 0.965; p < 0.001) with the ALBI score in the entire cohort and different subgroups of patients with hepatoma (36). With easy calculation and a more user-friendly assessment, the EZ-ALBI score can evaluate liver functional reserve in patients with liver diseases receiving various treatment modalities (35–39).

While the liver plays a significant role in producing albumin, there are several other factors that can impact the albumin levels in the body, especially in the context of trauma patients, including increased capillary permeability and fluid shifts, inflammatory response, malnutrition, and impaired renal function (40–47). In addition, the level of bilirubin, a breakdown product of hemoglobin from red blood cells and primarily processed and excreted by the liver, may be influenced not only by liver function but also by hemolysis and processing of cell-free hemoglobin from the circulation (48–50). Under the hypothesis that the EZ-ALBI score may be associated with the mortality risk of trauma patients, this study aimed to investigate whether the EZ-ALBI score serves as an independent risk factor for mortality and is useful for stratifying the mortality risk of adult patients with all trauma causes. In this study, the primary outcome was the in-hospital mortality rate.

Materials and methods

Ethics statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Chang Gung Memorial Hospital (protocol code 202201380B0 and date of approval 2022/09/15). The need for informed consent was waived according to the IRB regulations because of its retrospective study of design.

Study population and data collection

There were 46,808 hospitalized patients injured by all trauma causes in the Trauma Registry System of the Chang Gung Memorial Hospital between January 1, 2009, and December 31, 2021 (51–54) (Figure 1). Of the 41,131 adult patients aged ≥20 years, after excluding patients who lacked data on albumin or bilirubin (n = 36,432), those with burn injuries (n = 1,040), hanging injuries (n = 19), and patients who drowned (n = 3), 3,637 adult trauma patients were included in the study population. The major liver injuries indicated that the trauma patients had suffered an abbreviated injury scale (AIS) ≥ 3 liver injury in the abdomen. We retrieved the medical information of the study population from a registered trauma database. The data included sex, age, levels at admission of serum albumin, total bilirubin, glucose, white blood cells count, hemoglobin (Hb), hematocrit (Hct), platelets, aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine, trauma regions, trauma mechanism, pre-existing comorbidities, a Glasgow Coma Scale (GCS) score, an Injury Severity Score (ISS), hospital length of stay (LOS), and in-hospital mortality. The EZ-ALBI score was calculated according to the equation: total bilirubin (mg/dl) − 9 × albumin (g/dl).

Figure 1

Statistical analyses

Categorical data were compared using a two-sided Fisher's exact test. Normally distributed continuous data were estimated using the Kolmogorov–Smirnov test. Non-normally distributed continuous data were analyzed using the Mann–Whitney U-test, and continuous data with a normal distribution were compared using analysis of variance with Bonferroni post hoc correction. Continuous data are expressed as the mean ± standard deviation. Non-normal distributed continuous data are presented as medians with interquartile ranges (IQR) between Q1 and Q3. Multivariate logistic regression was used to analyze the univariate predictive variables, resulting in patient mortality and identify independent risk factors for mortality. The predictive performance of EZ-ALBI for patient mortality was determined based on the area under the curve (AUC) of the receiver operating characteristic curve (ROC). Based on a value determined using sensitivity + specificity − 1, the maximal Youden index, the best cutoff point was derived from ROC. In addition to the comparison between the death and survival groups of patients, a further comparison of the patients allocated into two groups based on the best cutoff point of the EZ-ALBI value was performed with the presentation of an adjusted odds ratio (AOR) of mortality with 95% confidence intervals (CIs), calculated using logistic regression under the control of variables with significant differences in patient injury characteristics. To effectively account for any initial differences in baseline characteristics among patient groups divided by the best cutoff point of the EZ-ALBI value, particularly the impact of different trauma mechanisms, a cohort with a 1:1 propensity score matching was created using the Greedy strategy with a caliper width of 0.2 and the NCSS 10 software (NCSS Statistical program, Kaysville, Utah, USA). The statistical analyses were performed using SPSS Statistics (version 23.0; IBM Corp., Armonk, NY, USA). Statistical significance was set at p < 0.05.

Results

Injury and patient characteristics

A comparison between 292 deceased and 3,345 surviving patients revealed that the non-survivors comprised significantly more males and were older than the surviving patients (Table 1). Patients who died had a significantly higher EZ-ALBI score than those who survived (−26.4 ± 6.5 vs. −31.5 ± 6.2, p < 0.001). The non-survivors had a significantly lower serum albumin level than the survivors (3.1 ± 0.8 vs. 3.6 ± 0.7, p < 0.001), while there was no significant difference in total bilirubin level between these two groups of patients (1.1 ± 0.9 vs. 1.0 ± 1.3, p = 0.173). The non-survivors had a significantly different level of glucose, AST, ALT, BUN, Cr than the survivors. The non-survivors had more incidences of AIS ≥ 3 injuries to head/neck and external body regions but fewer AIS ≥ 3 injuries to extremities than the survivors. Regarding comorbidities, significantly higher rates of pre-existing comorbidities of coronary artery disease (CAD), end-stage renal disease (ESRD), and liver cirrhosis were found in patients who died than in those who survived. Patients who died presented with a significantly lower GCS (median [IQR, Q1–Q3], GCS: 7 ([3–15]) vs. 15 ([13–15]), p < 0.001) but a higher ISS (25 ([16–29]) vs. 12 ([9–20]), p < 0.001) than patients who survived. Patients who died had a significantly shorter hospitalization period than those who survived (14.2 vs. 17.7 days, p = 0.001).

A comparison of the injuries and patient characteristics of the patients with and without major liver injuries revealed the patients with major liver injuries were significantly younger, had fewer incidences of HTN and DM, sustained significantly more severe injuries, and stayed longer in the hospital than those without major liver injuries (Table 2). However, these two groups of patients with or without major liver injury did not present significant differences in the level of albumin, total bilirubin, or the derived value of EZ-ALBI. The mortality and adjusted mortality corrected by age, incidences of HTN and DM, and ISS between the patients with and without major liver injuries did not present significant differences.

Analysis of the ROC curve

Based on the ROC analysis, the optimal albumin level was determined to be 3.33 g/dl, with a sensitivity of 0.600 and a specificity of 0.616 (Figure 2). The optimal EZ-ALBI score was determined to be −28.5, with a sensitivity of 0.637 and a specificity of 0.685 (Figure 2). Albumin alone and EZ-ALBI had AUCs of 0.67 and 0.72, respectively, as shown in Figure 2. The ability of EZ-ALBI alone to predict patient mortality was moderately accurate and superior to that of albumin alone (p = 0.046).

Figure 2

Analysis of the risk factors for mortality

Univariate analysis revealed that sex, age, the presence of EZ-ALBI score ≥ −28.5, the level of glucose, AST, ALT, BUN, Cr, the presence of an injury of AIS ≥ 3 in the head/neck, extremities, or external, the presence of CAD, ESRD, or liver cirrhosis, the GCS score, and the ISS were significant risk factors for mortality in the study population (Table 3). Multivariate logistic regression analysis of these risk factors revealed that the presence of EZ-ALBI score ≥ −28.5 (OR, 2.31; 95% CI, 1.63–3.28; p < 0.001) was an independent risk factor for mortality. Additionally, age (OR, 1.02; 95% CI, 1.01–1.04; p < 0.001), the glucose level (OR, 1.23; 95% CI, 1.05–1.45 p = 0.011), injury to the external body region (OR, 9.48; 95% CI, 1.76–50.96 p = 0.009), liver cirrhosis (OR, 2.87; 95% CI, 1.42–5.78; p = 0.003), GCS (OR, 0.86; 95% CI, 0.83–0.90; p < 0.001), and ISS (OR, 1.05; 95% CI, 1.03–1.07; p < 0.001) were significant independent risk factors for mortality in these patients.

The outcomes of patients with EZ-ALBI scores ≥ −28.5 vs. those with EZ-ALBI scores < −28.5

There was no significant difference in sex between patients with an EZ-ALBI score ≥ −28.5 and patients with an EZ-ALBI score < −28.5 (Table 4). Patients with an EZ-ALBI score ≥ −28.5 were significantly older than those with an EZ-ALBI score < −28.5 (p < 0.001). A significantly higher rate of an injury of AIS ≥ 3 in head/neck, thoracic, abdomen, and extremities body regions was found in patients with an EZ-ALBI score ≥ −28.5 compared to those with EZ-ALBI scores < −28.5. A significantly lower rate of pre-existing CVA, but no other comorbidities, was found in patients with an EZ-ALBI score ≥ −28.5 compared to those with EZ-ALBI scores < −28.5. Patients with an EZ-ALBI score ≥ −28.5 presented with a significantly lower GCS but a higher ISS than those with an EZ-ALBI score < −28.5 (GCS: 15 ([9–15]) vs. 15 ([14–15]), p < 0.001; ISS: 16 ([9–25]) vs. 9 ([8–18]), p < 0.001). Patients with an EZ-ALBI score ≥ −28.5 presented with a significantly higher mortality rate than patients with an EZ-ALBI score < −28.5 (15.1% vs. 4.4%, p < 0.001). Under the control of age, pre-existing CVA, GCS, and ISS, patients with an EZ-ALBI score ≥ −28.5 still presented with a significantly higher adjusted mortality rate than patients with an EZ-ALBI score < −28.5 (AOR, 2.47; 95% CI: 1.90–3.22, p = 0.001). Patients with an EZ-ALBI score ≥ −28.5 had significantly shorter hospitalization periods than those with an EZ-ALBI score < −28.5 (23.8 vs. 14.1 days, p = 0.001).

The outcomes of propensity score-matched cohort of patients with EZ-ALBI scores ≥ −28.5 vs. those with EZ-ALBI scores < −28.5

For patients with or without EZ-ALBI scores≥−28.5, a propensity score-matched patient cohort of 1:1 (Table 5) was established to reduce the influence of confounding factors related to the patients’ baseline characteristics of trauma mechanisms on outcome assessments. The propensity score-matched patient populations, comprising 1,236 pairings, exhibited no statistically significant variations in terms of trauma mechanisms, including traffic accidents, fall, strike by/against objects, suicide, and electric injury. Patients with an EZ-ALBI score≥−28.5 presented with a significantly higher mortality (OR, 4.12; 95% CI, 2.99–5.67, p <0.001) and longer LOS in the hospital (23.8 days vs. 14.8 days, p <0.001) than those with an EZ-ALBI score<−28.5.

Discussion

In this study, patients who died were significantly associated with a higher EZ-ALBI score than those who survived, and those with an EZ-ALBI score ≥ −28.5 presented with a 2.47-fold adjusted mortality rate compared to patients with an EZ-ALBI score < −28.5. The analysis in a propensity score-matched pair cohort of 1,236 patients, which was developed to reduce baseline disparities in trauma mechanisms, also showed that patients with an EZ-ALBI score ≥ −28.5 had a 4.12 times higher mortality rate compared to patients with an EZ-ALBI score < −28.5. The results revealed that the EZ-ALBI score was a significant independent risk factor for mortality in adult trauma patients due to all trauma causes and presented with a significant better predictive power for mortality than the use of albumin alone. Therefore, EZ-ALBI may serve as a valuable tool to stratify the mortality risk of adult trauma patients.

The severity of liver dysfunction is often estimated using the MELD score or CTP classification. MELD is a continuous score derived from the calculation of serum creatinine and bilirubin levels and the international normalized PT ratio (55–57). However, MELD has been widely adopted for end-stage cirrhotic patients awaiting liver transplantation (2) and is specifically designed for patients with end-stage cirrhosis (58–60). The application of the MELD score in patients with less severe liver dysfunction has been criticized (4). In addition, the CTP classification system incorporates five different factors, including serum levels of total bilirubin, albumin, and prothrombin time, and two clinical symptom indicators, ascites and hepatic encephalopathy (3). It has been argued that the variable of ascites is intercorrelated with albumin, whereas it is difficult to subjectively assess and consistently score ascites and hepatic encephalopathy among different investigators (61); and the CTP score is limited by the arbitrary determination of cutoff values of objective laboratory variables with equal weighting of five parameters (62). Moreover, a literature review revealed that there were more than 30 versions of the CTP classification, making it difficult to achieve consistent scoring (63). Hence, the potential superiority of EZ-ALBI over CTP as a prognostic indicator for death in trauma patients is an intriguing subject that warrants additional research and exploration.

The EZ-ALBI score is a combination of two indicators, total bilirubin and albumin, which include both metabolic function (total bilirubin) and synthesis function (albumin) of the liver (64). Albumin and bilirubin levels are also frequently measured as part of the assessment of liver function and general health when conducting clinical practice. Increased serum bilirubin concentrations frequently indicate variable degrees of liver failure, serving as a predictor of liver performance in many prognostic models such as the Acute Physiology and Chronic Health Evaluation (APACHE) score (65), the Sequential Organ Failure Assessment (SOFA) score (66), Simplified Acute Physiology Score (SAPS II) (67), Logistic Organ Dysfunction Score (LODS) (68), and Multiple Organ Dysfunction Score (MODS) (69). Around 40 percent of critically ill patients have elevated bilirubin levels in the blood, which is associated with increased mortality and adverse outcomes (70). In addition, the decreased level of albumin, which is synthesized in the liver, suggests dysfunction in liver synthesis and malnutrition. Hypoalbuminemia may indicate malnutrition or inflammation, both of which are common in hospitalized patients (71). Inadequate albumin levels may lead to fluid imbalances, potentially producing edema, interfering with heart function, and increasing characteristics associated with poorer outcomes in trauma patients (72–75). Furthermore, albumin levels may indicate the degree of damage and total physiological stress, acting as a predictor of complications, prolonged ICU admission, and higher mortality risk (71). However, in contrast to bilirubin, albumin levels were not generally regarded as a principal variable in the majority of intensive care unit prediction models. Notably, these two groups of patients did not present significant differences in the level of albumin, total bilirubin, or the derived value of EZ-ALBI. The mortality and adjusted mortality corrected by age, incidences of HTN and DM, and ISS between the patients with and without major liver injuries did not present significant differences. It should be recognized that the liver dysfunction is not the only way for albumin and bilirubin to be changed by trauma. Although the mechanism underlying the prognostic impact of albumin and bilirubin remains undetermined, the ALBI approach based on laboratory data avoids interobserver variation and is superior to CTP in identifying patients with distinct prognostic subgroups within CTP (65). With easy calculation and assessment, EZ-ALBI may serve as a useful marker to help identify adult trauma patients with a high mortality risk.

This study has some limitations. First, there may have been a selection bias due to the retrospective design of this study. Second, management, such as damage control, blood transfusion, resuscitation, and surgical interventions, could have led to different outcomes in the study population; Furthermore, the physiology and nutritional condition, the laboratory data presented in the emergency room, the trauma mechanisms, and the injured regions can influence the patients' survival. All of these factors may introduce bias into the relationship assessment with the mortality outcome; however, we can only assume that the outcomes of these methods were uniform across the study population. Third, this study evaluated only in-hospital mortality and not the death declared upon arrival at the emergency room or long-term mortality; therefore, a selection bias may exist regarding comparing the outcomes. In addition, the exclusion of patients due to lack of bilirubin and albumin data resulted in the exclusion of a vast majority of trauma patients and may have resulted in selection bias. Fourth, this study included trauma patients due to all trauma causes and did not specify or exclude patients with liver injury. The impact of the liver injury on the application of EZ-ALBI in patients with trauma deserves further investigation. Finally, the study population was limited to a single urban trauma center; therefore, the generalizability of the results to other regions may be limited.

Conclusion

This study revealed that the EZ-ALBI score was a significant independent risk factor for mortality and can serve as a valuable tool for stratifying mortality risk in adult trauma patients by all trauma causes.

References

• 1.

  D'AmicoGMorabitoAD'AmicoMPastaLMaliziaGReboraPet alClinical states of cirrhosis and competing risks. J Hepatol. (2018) 68(3):563–76. 10.1016/j.jhep.2017.10.020

  • CrossRef
  • Google Scholar

• 2.

  SingalAKKamathPS. Model for end-stage liver disease. J Clin Exp Hepatol. (2013) 3(1):50–60. 10.1016/j.jceh.2012.11.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3.

  CholongitasESenzoloMPatchDShawSHuiCBurroughsAK. Review article: scoring systems for assessing prognosis in critically ill adult cirrhotics. Aliment Pharmacol Ther. (2006) 24(3):453–64. 10.1111/j.1365-2036.2006.02998.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4.

  JohnsonPJBerhaneSKagebayashiCSatomuraSTengMReevesHLet alAssessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. (2015) 33(6):550–8. 10.1200/jco.2014.57.9151

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5.

  LiuPHHsuCYHsiaCYLeeYHChiouYYHuangYHet alALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD era. J Gastroenterol Hepatol. (2017) 32(4):879–86. 10.1111/jgh.13608

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6.

  DemirtasCOD'AlessioARimassaLSharmaRPinatoDJ. ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep. (2021) 3(5):100347. 10.1016/j.jhepr.2021.100347

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7.

  MarascoGAlemanniLVColecchiaAFestiDBazzoliFMazzellaGet alPrognostic value of the albumin-bilirubin grade for the prediction of post-hepatectomy liver failure: a systematic review and meta-analysis. J Clin Med. (2021) 10(9):2011. 10.3390/jcm10092011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8.

  MishraGMajeedADevAEslickGDPinatoDJIzumotoHet alClinical utility of albumin bilirubin grade as a prognostic marker in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a systematic review and meta-analysis. J Gastrointest Cancer. (2022) 54(2):420–32. 10.1007/s12029-022-00832-0

  • CrossRef
  • Google Scholar

• 9.

  YoungLBTabrizianPSungJBiedermanDBishayVLRanadeMet alSurvival analysis using albumin-bilirubin (ALBI) grade for patients treated with drug-eluting embolic transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. (2022) 33(5):510–7.e1. 10.1016/j.jvir.2022.02.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10.

  AzarADevcicZPaz-FumagalliRVidalLLCMcKinneyJMFreyGet alAlbumin-bilirubin grade as a prognostic indicator for patients with non-hepatocellular primary and metastatic liver malignancy undergoing yttrium-90 radioembolization using resin microspheres. J Gastrointest Oncol. (2020) 11(4):715–23. 10.21037/jgo.2020.04.01

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11.

  GengLZongRShiYXuK. Prognostic role of preoperative albumin-bilirubin grade on patients with hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. (2020) 32(7):769–78. 10.1097/meg.0000000000001618

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12.

  PangQZhouSLiuSLiuHLuZ. Prognostic role of preoperative albumin-bilirubin score in posthepatectomy liver failure and mortality: a systematic review and meta-analysis. Updates Surg. (2022) 74(3):821–31. 10.1007/s13304-021-01080-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13.

  CampaniCBamba-FunckJCampionBSidaliSBlaiseLGanne-CarriéNet alBaseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab. Liver Int. (2023) 43(3):708–17. 10.1111/liv.15487

  • CrossRef
  • Google Scholar

• 14.

  ChenCWKuoCJLeeCWKuoTChiuCTLinCJet alAlbumin-bilirubin grade as a novel predictor of the development and short-term survival of post-banding ulcer bleeding following endoscopic variceal ligation in cirrhotic patients. Medicina (Kaunas). (2022) 58(12):1836. 10.3390/medicina58121836

  • CrossRef
  • Google Scholar

• 15.

  KimTHKimBHParkJWChoYRKohYHChunJWet alProton beam therapy for treatment-naïve hepatocellular carcinoma and prognostic significance of albumin-bilirubin (ALBI) grade. Cancers (Basel). (2022) 14(18):4445. 10.3390/cancers14184445

  • CrossRef
  • Google Scholar

• 16.

  ShiXRXuXYZhangGLJiangJYCaoDD. The prognostic role of albumin-bilirubin grade in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Eur Rev Med Pharmacol Sci. (2022) 26(20):7687–94. 10.26355/eurrev_202210_30045

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17.

  WangRKatzDLinHMOuyangYGalJSureshSet alA retrospective study of the role of perioperative serum albumin and the albumin-bilirubin grade in predicting post-liver transplant length of stay. Semin Cardiothorac Vasc Anesth. (2023) 27(1):16–24. 10.1177/10892532221141138

  • CrossRef
  • Google Scholar

• 18.

  XuFQYeTWWangDDXieYMZhangKJChengJet alAssociation of preoperative albumin-bilirubin with surgical textbook outcomes following laparoscopic hepatectomy for hepatocellular carcinoma. Front Oncol. (2022) 12:964614. 10.3389/fonc.2022.964614

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19.

  ToyodaHJohnsonPJ. The ALBI score: from liver function in patients with HCC to a general measure of liver function. JHEP Rep. (2022) 4(10):100557. 10.1016/j.jhepr.2022.100557

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20.

  TsilimigrasDIHyerJMMorisDSaharaKBaganteFGuglielmiAet alPrognostic utility of albumin-bilirubin grade for short- and long-term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 706 patients. J Surg Oncol. (2019) 120(2):206–13. 10.1002/jso.25486

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21.

  NiJYAnCZhangTQHuangZMJiangXYHuangJH. Predictive value of the albumin-bilirubin grade on long-term outcomes of CT-guided percutaneous microwave ablation in intrahepatic cholangiocarcinoma. Int J Hyperthermia. (2019) 36(1):328–36. 10.1080/02656736.2019.1567834

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22.

  Abdel-RahmanO. Prognostic value of baseline ALBI score among patients with colorectal liver metastases: a pooled analysis of two randomized trials. Clin Colorectal Cancer. (2019) 18(1):e61–8. 10.1016/j.clcc.2018.09.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23.

  SakinASahinSSakinAAtciMMYasarNAriciSet alAssessment of pretreatment albumin-bilirubin grade in pancreatic cancer patients with liver metastasis. J Buon Jul. (2020) 25(4):1941–6. .

  • Pubmed Abstract
  • Google Scholar

• 24.

  ItoTIshigamiMMorookaHYamamotoKImaiNIshizuYet alThe albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC. Sci Rep. (2020) 10(1):17812. 10.1038/s41598-020-74732-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25.

  KandaMTanakaCKobayashiDUdaHInaokaKTanakaYet alPreoperative albumin-bilirubin grade predicts recurrences after radical gastrectomy in patients with pT2-4 gastric cancer. World J Surg. (2018) 42(3):773–81. 10.1007/s00268-017-4234-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26.

  KinoshitaFYamashitaTOkuYKosaiKOnoYWakasuSet alPrognostic impact of albumin-bilirubin (ALBI) grade on non-small lung cell carcinoma: a propensity-score matched analysis. Anticancer Res. (2021) 41(3):1621–8. 10.21873/anticanres.14924

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27.

  MatsukaneRWatanabeHHataKSuetsuguKTsujiTEgashiraNet alPrognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. Sci Rep. (2021) 11(1):15057. 10.1038/s41598-021-94336-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28.

  AoyamaTJuMMachidaDKomoriKTamagawaHTamagawaAet alClinical impact of preoperative albumin-bilirubin Status in esophageal cancer patients who receive curative treatment. In Vivo. (2022) 36(3):1424–31. 10.21873/invivo.12847

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29.

  ZhangJXuQZhangHZhangYYangYLuoHet alHigh preoperative albumin-bilirubin score predicts poor survival in patients with newly diagnosed high-grade gliomas. Transl Oncol. (2021) 14(4):101038. 10.1016/j.tranon.2021.101038

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30.

  ZhuSChengZHuYChenZZhangJKeCet alPrognostic value of the systemic immune-inflammation index and prognostic nutritional Index in patients with medulloblastoma undergoing surgical resection. Front Nutr. (2021) 8:754958. 10.3389/fnut.2021.754958

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31.

  KawataTIkedaAMasudaHKomatsuS. Association between albumin-bilirubin score at admission and in-hospital mortality in patients with acute heart failure. Int Heart J. (2021) 62(4):829–36. 10.1536/ihj.21-080

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32.

  HanSWangCTongFLiYLiZSunZet alPrognostic impact of albumin-bilirubin score on the prediction of in-hospital mortality in patients with heart failure: a retrospective cohort study. BMJ Open. (2022) 12(1):e049325. 10.1136/bmjopen-2021-049325

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33.

  ShiLZhangDZhangJ. Albumin-bilirubin score is associated with in-hospital mortality in critically ill patients with acute pancreatitis. Eur J Gastroenterol Hepatol. (2020) 32(8):963–70. 10.1097/meg.0000000000001753

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34.

  LiuJWuMXieEChenLSuSZengHet alAssessment of liver function for evaluation of short- and long-term outcomes in type B aortic dissection patients undergoing thoracic endovascular aortic repair. Front Cardiovasc Med. (2021) 8:643127. 10.3389/fcvm.2021.643127

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35.

  KariyamaKNousoKHiraokaAWakutaAOonishiAKuzuyaTet alEZ-ALBI score for predicting hepatocellular carcinoma prognosis. Liver Cancer. (2020) 9(6):734–43. 10.1159/000508971

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36.

  HoSYLiuPHHsuCYKoCCHuangYHSuCWet alEasy albumin-bilirubin score as a new prognostic predictor in hepatocellular carcinoma. Hepatol Res. (2021) 51(11):1129–38. 10.1111/hepr.13671

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37.

  AnanchuensookPSriphoosanaphanSSuksawatamnauySSiriponNPinjaroenNGeratikornsupukNet alValidation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization. BMC Gastroenterol. (2022) 22(1):295. 10.1186/s12876-022-02366-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38.

  HoSYLiuPHHsuCYHuangYHLiaoJISuCWet alTumor burden score as a new prognostic surrogate in patients with hepatocellular carcinoma undergoing radiofrequency ablation: role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Expert Rev Gastroenterol Hepatol. (2022) 16(9):903–11. 10.1080/17474124.2022.2117156

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39.

  HoSYYuanMHLiuPHHsuCYHuangYHLiaoJIet alCryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Scand J Gastroenterol. (2022) 58(1):61–9. 10.1080/00365521.2022.2098052

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40.

  LiSZhangJZhengHWangXLiuZSunT. Prognostic role of serum albumin, total lymphocyte count, and mini nutritional assessment on outcomes after geriatric hip fracture surgery: a meta-analysis and systematic review. J Arthroplasty. (2019) 34(6):1287–96. 10.1016/j.arth.2019.02.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41.

  MizrahiEHFleissigYAradMBlumsteinTAdunskyA. Admission albumin levels and functional outcome of elderly hip fracture patients: is it that important?Aging Clin Exp Res. (2007) 19(4):284–9. 10.1007/bf03324703

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42.

  Aguirre PuigPOrallo MoránMAPereira MatalobosDPrieto RequeijoP. Current role of albumin in critical care [papel actual de la albúmina en cuidados críticos]. Rev Esp Anestesiol Reanim. (2014) 61(9):497–504. 10.1016/j.redar.2014.04.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43.

  CabrerizoSCuadrasDGomez-BustoFArtaza-ArtabeIMarín-CiancasFMalafarinaV. Serum albumin and health in older people: review and meta analysis. Maturitas. (2015) 81(1):17–27. 10.1016/j.maturitas.2015.02.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44.

  CartottoRCallumJ. A review of the use of human albumin in burn patients. J Burn Care Res. Nov. (2012) 33(6):702–17. 10.1097/BCR.0b013e31825b1cf6

  • CrossRef
  • Google Scholar

• 45.

  HülshoffASchrickerTElgendyHHatzakorzianRLattermannR. Albumin synthesis in surgical patients. Nutrition. (2013) 29(5):703–7. 10.1016/j.nut.2012.10.014

  • CrossRef
  • Google Scholar

• 46.

  MaiminDGLaubscherMMaqungoSMaraisLC. Hypoalbuminaemia in orthopaedic trauma patients in a rural hospital in South Africa. Int Orthop. (2022) 46(1):37–42. 10.1007/s00264-021-05022-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47.

  WiedermannCJ. Moderator effect of hypoalbuminemia in volume resuscitation and plasma expansion with intravenous albumin solution. Int J Mol Sci. (2022) 23(22):14175. 10.3390/ijms232214175

  • CrossRef
  • Google Scholar

• 48.

  CorronsJLVCasafontLBFrasnedoEF. Concise review: how do red blood cells born, live, and die?Ann Hematol. (2021) 100(10):2425–33. 10.1007/s00277-021-04575-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49.

  RandolphVS. Four clinical chemistry analyses for pediatric patients: glycosylated hemoglobin, free bilirubin, sweat electrolytes, neonatal thyroxine. Am J Med Technol. (1982) 48(1):15–22. .

  • Pubmed Abstract
  • Google Scholar

• 50.

  RobinsonSH. Bilirubin metabolism and jaundice. Pathobiol Annu. (1976) 6:299–316. .

  • Pubmed Abstract
  • Google Scholar

• 51.

  HsiehCHHsuSYHsiehHYChenYC. Differences between the sexes in motorcycle-related injuries and fatalities at a Taiwanese level I trauma center. Biomed J. (2017) 40(2):113–20. 10.1016/j.bj.2016.10.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52.

  HsiehCHLiuHTHsuSYHsiehHYChenYC. Motorcycle-related hospitalizations of the elderly. Biomed J. (2017) 40(2):121–8. 10.1016/j.bj.2016.10.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53.

  HsiehCHChenYCHsuSYHsiehHYChienPC. Defining polytrauma by abbreviated injury scale >/=3 for a least two body regions is insufficient in terms of short-term outcome: a cross-sectional study at a level I trauma center. Biomed J. (2018) 41(5):321–7. 10.1016/j.bj.2018.08.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54.

  TsaiCHRauCSChouSESuWTHsuSYHsiehCH. Delta De ritis ratio is associated with worse mortality outcomes in adult trauma patients with moderate-to-severe traumatic brain injuries. Diagnostics (Basel). (2022) 12(12):3004. 10.3390/diagnostics12123004

  • CrossRef
  • Google Scholar

• 55.

  Bayona MolanoMDPBarrera GutierrezJCLandinezGMejiaAHaskalZJ. Updates of the MELD score and impact on the liver transplant waiting list: a narrative review. J Vasc Interv Radiol. (2023) 34(3):337–43. 10.1016/j.jvir.2022.12.029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56.

  GeJKimWRLaiJCKwongAJ. “Beyond MELD”—emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation. J Hepatol. (2022) 76(6):1318–29. 10.1016/j.jhep.2022.03.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57.

  SharmaP. Value of liver function tests in cirrhosis. J Clin Exp Hepatol. (2022) 12(3):948–64. 10.1016/j.jceh.2021.11.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58.

  BruixJShermanM. Management of hepatocellular carcinoma. Hepatology. (2005) 42(5):1208–36. 10.1002/hep.20933

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59.

  BruixJShermanM. Management of hepatocellular carcinoma: an update. Hepatology. (2011) 53(3):1020–2. 10.1002/hep.24199

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60.

  BottaFGianniniERomagnoliPFasoliAMalfattiFChiarbonelloBet alMELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut. (2003) 52(1):134–9. 10.1136/gut.52.1.134

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61.

  KnoxJJ. Addressing the interplay of liver disease and hepatocellular carcinoma on patient survival: the ALBI scoring model. J Clin Oncol. (2015) 33(6):529–31. 10.1200/jco.2014.59.0521

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 62.

  ChanAWKumadaTToyodaHTadaTChongCCMoFKet alIntegration of albumin-bilirubin (ALBI) score into Barcelona clinic liver cancer (BCLC) system for hepatocellular carcinoma. J Gastroenterol Hepatol. (2016) 31(7):1300–6. 10.1111/jgh.13291

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 63.

  JohnsonPJPinatoDJKalyuzhnyyAToyodaH. Breaking the child-pugh dogma in hepatocellular carcinoma. J Clin Oncol. (2022) 40(19):2078–82. 10.1200/jco.21.02373

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64.

  YeLLiangRZhangJChenCChenXZhangYet alPostoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy. Ann Transl Med. (2019) 7(16):367. 10.21037/atm.2019.06.01

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65.

  KnausWAWagnerDPDraperEAZimmermanJEBergnerMBastosPGet alThe APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. (1991) 100(6):1619–36. 10.1378/chest.100.6.1619

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 66.

  VincentJLMorenoRTakalaJWillattsSDe MendonçaABruiningHet alThe SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med. (1996) 22(7):707–10. 10.1007/bf01709751

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 67.

  Le GallJRLemeshowSSaulnierF. A new simplified acute physiology score (SAPS II) based on a European/north American multicenter study. JAMA. (1993) 270(24):2957–63. 10.1001/jama.270.24.2957

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 68.

  HeldweinMBBadreldinAMDoerrFLehmannTBayerODoenstTet alLogistic organ dysfunction score (LODS): a reliable postoperative risk management score also in cardiac surgical patients?J Cardiothorac Surg. (2011) 6:110. 10.1186/1749-8090-6-110

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69.

  MacGregorDAPrielippRC. Multiple organ dysfunction score. Crit Care Med. (1996) 24(7):1272–3. 10.1097/00003246-199607000-00036

  • CrossRef
  • Google Scholar

• 70.

  SingerMDeutschmanCSSeymourCWShankar-HariMAnnaneDBauerMet alThe third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. (2016) 315(8):801–10. 10.1001/jama.2016.0287

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71.

  SoetersPBWolfeRRShenkinA. Hypoalbuminemia: pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr. (2019) 43(2):181–93. 10.1002/jpen.1451

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72.

  Alderson P, Bunn F, Lefebvre C, Li WP, Li L, Roberts I, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev. (2011) (10):Cd001208. 10.1002/14651858.CD001208.pub3

  • CrossRef
  • Google Scholar

• 73.

  RobertsIBlackhallKAldersonPBunnFSchierhoutG. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev. (2011) 2011(11):Cd001208. 10.1002/14651858.CD001208.pub4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 74.

  FrazeeEKashaniK. Fluid management for critically ill patients: a review of the current state of fluid therapy in the intensive care unit. Kidney Dis (Basel). (2016) 2(2):64–71. 10.1159/000446265

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75.

  PinatoDJSharmaRAllaraEYenCArizumiTKubotaKet alThe ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. (2017) 66(2):338–46. 10.1016/j.jhep.2016.09.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar